Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda Licenses Prostate Cancer Vaccine from Cell Genesys
April 14, 2008
- Alimta Receives Positive CHMP Opinion for NSCLC First-Line Treatment: Eli Lilly
April 14, 2008
- Antidepressants Often Used Off-Label to Treat Chronic Pain
April 14, 2008
- Takeda Ties Up with JPRI for Sabin-Inactivated Poliovirus Vaccine
April 14, 2008
- REGULATORY NEWS IN BRIEF
April 14, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 14, 2008
- Asahi Kasei to License New Products to Strengthen Its R&D Pipeline
April 14, 2008
- TOPICS／Olopatadine Receives 2008 PSJ Award for Drug R&D 2008
April 14, 2008
- DSP to Choose 2nd Global Strategic Product by Fall
April 14, 2008
- Chugai Reinforces European Sales Structure
April 14, 2008
- Kirin Pharma, Kyowa Hakko Announce Restructuring of R&D Systems
April 14, 2008
- Mochida to Undertake Challenges in New Fields
April 14, 2008
- Industry Calls For Development of Toxicity Screening Tools Using iPS Cells
April 14, 2008
- Mediceo Paltac to Offer Prices to All Customers within April
April 14, 2008
- J-CLIPNET Ties Up with KoNECT of South Korea
April 14, 2008
- Korosho Asks Semi-Public Hospital Groups, Idaikyo, to Cooperate to Improve Business Practices
April 14, 2008
- R&D NEWS IN BRIEF
April 14, 2008
- BUSINESS NEWS IN BRIEF
April 14, 2008
- JACRI Approves Mid-Term Strategy to Expand Market for Reagents
April 14, 2008
- Mitsuo Sawai to Be Promoted to President of Sawai Pharm.
April 14, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…